Industry Overview

North America anticoagulants market was valued at $17.7 billion in 2025 and is projected to reach $28.7 billion by 2035, growing at a CAGR of 5.1% during the forecast period (2026–2035). The North American anticoagulants market is recording consistent expansion as long-term thrombotic risk management becomes central to cardiovascular care strategies. Broader diagnostic coverage and proactive treatment protocols are contributing to sustained prescription volumes. Healthcare systems across the United States and Canada continue to prioritize therapies that reduce hospitalization risk associated with clot-related complications. Bristol Myers Squibb, together with Pfizer Inc., markets Eliquis, which holds a strong position in stroke prevention therapy. Its continued inclusion in payer formularies supports recurring utilization.

Market Dynamics

Continued Dominance of Direct Oral Anticoagulants

The North American anticoagulants market continues to be shaped by the widespread clinical preference for direct oral anticoagulants over traditional therapies. Physicians increasingly favor treatments that offer predictable dosing and reduced monitoring requirements. Strong reimbursement structures across the United States and Canada support consistent patient access. Bristol Myers Squibb, in collaboration with Pfizer Inc., markets Eliquis, which maintains substantial prescription volumes across the region. Its established role in stroke prevention for atrial fibrillation reinforces long-term utilization. This sustained uptake continues to anchor regional market revenues.

Expansion of Anticoagulation in Cardiovascular Risk Management

Rising prevalence of cardiovascular disorders, including atrial fibrillation and thromboembolic conditions, is contributing to consistent demand for anticoagulant therapy in North America. Preventive cardiology initiatives and routine screening programs are identifying patients earlier in the disease course. Healthcare providers are increasingly integrating anticoagulants into comprehensive care pathways. Johnson & Johnson co-markets Xarelto in the United States, supporting treatment across multiple thrombotic indications. The drug’s established clinical positioning sustains repeat prescriptions. Such therapeutic continuity is reinforcing steady market growth across the region.

Market Segmentation

• Based on the type, the market is segmented into novel oral anticoagulants, vitamin K antagonists, and heparin and low molecular weight heparin.
• Based on the application, the market is segmented into pulmonary embolism, atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis, and others.

Low Molecular Weight Heparin Segment to Lead the Market with the Largest Share

The North American anticoagulants market continues to register stable growth, supported by the sustained use of low molecular weight heparins in inpatient care. These agents remain integral to thromboprophylaxis protocols following major surgical procedures and trauma management. Their predictable anticoagulant response supports routine administration within hospital settings. Sanofi supplies Lovenox across the United States and Canada, maintaining consistent institutional demand. Procurement through group purchasing organizations ensures regular supply cycles.

Atrial Fibrillation/Myocardial Infarction (Heart Attack): A Key Segment in Market Growth

Growth in the region is also closely associated with the ongoing management of atrial fibrillation and post-myocardial infarction complications. Cardiologists increasingly emphasize long-term stroke prevention strategies in high-risk patient populations. Continuous therapy and structured follow-up programs support sustained prescription adherence. Johnson & Johnson co-markets Xarelto in the United States for stroke prevention in non-valvular atrial fibrillation. Its established presence in cardiovascular treatment guidelines supports continued utilization.

Regional Outlook

North America anticoagulants market is further divided by countries, including the US and Canada.

US Dominates the Market with Major Share

The US anticoagulants market is advancing steadily as preventive cardiovascular care remains a strategic priority within healthcare systems. Expanded screening initiatives and improved risk stratification tools are increasing the number of patients eligible for anticoagulation therapy. Strong payer coverage frameworks facilitate patient access to established branded therapies. Bristol Myers Squibb and Pfizer Inc. jointly commercialize Eliquis, which maintains substantial prescription volumes nationwide. Its continued inclusion in major insurance formularies sustains recurring sales.

Market Players Outlook

The major companies operating in the North America anticoagulants market include AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., and Roche, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In July 2025, the Bristol Myers Squibb-Pfizer Alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the Alliance’s patient resource Eliquis 360 Support. The offering provides an opportunity for uninsured, underinsured, self-pay patients to significantly lower their out-of-pocket costs for this critical medicine. Eliquis is relied upon by millions of Americans daily, and this program will provide a simple and transparent way to access it.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the North America anticoagulants market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.